help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schroeder, M. D.
Right arrow Articles by Schuler, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schroeder, M. D.
Right arrow Articles by Schuler, L. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
Molecular Endocrinology 16 (1): 45-57
Copyright © 2002 by The Endocrine Society

PRL Modulates Cell Cycle Regulators in Mammary Tumor Epithelial Cells

Matthew D. Schroeder, Jaime Symowicz and Linda A. Schuler

Department of Comparative Biosciences, University of Wisconsin, Madison, Wisconsin 53706

Address all correspondence and requests for reprints to: Dr. L. A. Schuler, Department of Comparative Biosciences, University of Wisconsin, 2015 Linden Drive West, Madison, Wisconsin 53706. E-mail: schulerl{at}svm.vetmed.wisc.edu

PRL is essential for normal lobulo-alveolar growth of the mammary gland and may contribute to mammary cancer development or progression. However, analysis of the mechanism of action of PRL in these processes is complicated by the production of PRL within mammary epithelia. To examine PRL actions in a mammary cell-specific context, we selected MCF-7 cells that lacked endogenous PRL synthesis, using PRL stimulation of interferon-{gamma}-activated sequence-related PRL response elements. Derived clones exhibited a greater proliferative response to PRL than control cells. To understand the mechanism, we examined, by Western analysis, levels of proteins essential for cell cycle progression as well as phosphorylation of retinoblastoma protein. The expression of cyclin D1, a critical regulator of the G1/S transition, was significantly increased by PRL and was associated with hyperphosphorylation of retinoblastoma protein at Ser780. Cyclin B1 was also increased by PRL. In contrast, PRL decreased the Cip/Kip family inhibitor, p21, but not p16 or p27. These studies demonstrate that PRL can stimulate the cell cycle in mammary epithelia and identify specific targets in this process. This model system will enable further molecular dissection of the pathways involved in PRL-induced proliferation, increasing our understanding of this hormone and its interactions with other factors in normal and pathogenic processes.




This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
K. C. Carver and L. A. Schuler
Prolactin Does Not Require Insulin-Like Growth Factor Intermediates but Synergizes with Insulin-Like Growth Factor I in Human Breast Cancer Cells
Mol. Cancer Res., April 1, 2008; 6(4): 634 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. W. Harvey, D. J. Everett, and C. J. Springall
Adverse effects of prolactin in rodents and humans: breast and prostate cancer.
J Psychopharmacol, March 1, 2008; 22(2 Suppl): 20 - 27.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee
What Can We Learn from Rodents about Prolactin in Humans?
Endocr. Rev., February 1, 2008; 29(1): 1 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. M. Arendt and L. A. Schuler
Prolactin Drives Estrogen Receptor-{alpha}-Dependent Ductal Expansion and Synergizes with Transforming Growth Factor-{alpha} to Induce Mammary Tumors in Males
Am. J. Pathol., January 1, 2008; 172(1): 194 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Ge, C. A. Fernandez, M. A. Moses, and D. S. Greenspan
Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor
PNAS, June 12, 2007; 104(24): 10010 - 10015.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
O. Eyal, J.-B. Jomain, C. Kessler, V. Goffin, and S. Handwerger
Autocrine Prolactin Inhibits Human Uterine Decidualization: A Novel Role for Prolactin
Biol Reprod, May 1, 2007; 76(5): 777 - 783.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Tworoger, A. H. Eliassen, P. Sluss, and S. E. Hankinson
A Prospective Study of Plasma Prolactin Concentrations and Risk of Premenopausal and Postmenopausal Breast Cancer
J. Clin. Oncol., April 20, 2007; 25(12): 1482 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. P Wiebe
Progesterone metabolites in breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 717 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
P W Harvey, D J Everett, and C J Springall
Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer
Human and Experimental Toxicology, July 1, 2006; 25(7): 395 - 404.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
L. M. Arendt, T. A. Rose-Hellekant, E. P. Sandgren, and L. A. Schuler
Prolactin Potentiates Transforming Growth Factor {alpha} Induction of Mammary Neoplasia in Transgenic Mice
Am. J. Pathol., April 1, 2006; 168(4): 1365 - 1374.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Tworoger, P. Sluss, and S. E. Hankinson
Association between Plasma Prolactin Concentrations and Risk of Breast Cancer among Predominately Premenopausal Women
Cancer Res., February 15, 2006; 66(4): 2476 - 2482.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-C. Lu, T. M. Piazza, and L. A. Schuler
Proteasomes Mediate Prolactin-induced Receptor Down-regulation and Fragment Generation in Breast Cancer Cells
J. Biol. Chem., October 7, 2005; 280(40): 33909 - 33916.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. P. Tabruyn, N.-Q.-N. Nguyen, A. M. Cornet, J. A. Martial, and I. Struman
The Antiangiogenic Factor, 16-kDa Human Prolactin, Induces Endothelial Cell Cycle Arrest by Acting at Both the G0-G1 and the G2-M Phases
Mol. Endocrinol., July 1, 2005; 19(7): 1932 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. H. Gutzman, S. E. Nikolai, D. E. Rugowski, J. J. Watters, and L. A. Schuler
Prolactin and Estrogen Enhance the Activity of Activating Protein 1 in Breast Cancer Cells: Role of Extracellularly Regulated Kinase 1/2-Mediated Signals to c-fos
Mol. Endocrinol., July 1, 2005; 19(7): 1765 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly
Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists
Endocr. Rev., May 1, 2005; 26(3): 400 - 422.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. H. Gutzman, D. E. Rugowski, M. D. Schroeder, J. J. Watters, and L. A. Schuler
Multiple Kinase Cascades Mediate Prolactin Signals to Activating Protein-1 in Breast Cancer Cells
Mol. Endocrinol., December 1, 2004; 18(12): 3064 - 3075.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Tworoger, A. H. Eliassen, B. Rosner, P. Sluss, and S. E. Hankinson
Plasma Prolactin Concentrations and Risk of Postmenopausal Breast Cancer
Cancer Res., September 15, 2004; 64(18): 6814 - 6819.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. M. Karp, H. Pan, M. Zhang, D. J. Buckley, L. A. Schuler, and A. R. Buckley
Identification of HRPAP20: A Novel Phosphoprotein that Enhances Growth and Survival in Hormone-Responsive Tumor Cells
Cancer Res., February 1, 2004; 64(3): 1016 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. D. Schroeder, J. L. Brockman, A. M. Walker, and L. A. Schuler
Inhibition of Prolactin (PRL)-Induced Proliferative Signals in Breast Cancer Cells by a Molecular Mimic of Phosphorylated PRL, S179D-PRL
Endocrinology, December 1, 2003; 144(12): 5300 - 5307.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. J. Acosta, R. M. Munoz, L. Gonzalez, A. Subtil-Rodriguez, M. A. Dominguez-Caceres, J. M. Garcia-Martinez, A. Calcabrini, I. Lazaro-Trueba, and J. Martin-Perez
Src Mediates Prolactin-Dependent Proliferation of T47D and MCF7 Cells via the Activation of Focal Adhesion Kinase/Erk1/2 and Phosphatidylinositol 3-Kinase Pathways
Mol. Endocrinol., November 1, 2003; 17(11): 2268 - 2282.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. B. Kabotyanski and J. M. Rosen
Signal Transduction Pathways Regulated by Prolactin and Src Result in Different Conformations of Activated Stat5b
J. Biol. Chem., May 2, 2003; 278(19): 17218 - 17227.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. V. Clevenger, P. A. Furth, S. E. Hankinson, and L. A. Schuler
The Role of Prolactin in Mammary Carcinoma
Endocr. Rev., February 1, 2003; 24(1): 1 - 27.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Graichen, D. Liu, Y. Sun, K.-O. Lee, and P. E. Lobie
Autocrine Human Growth Hormone Inhibits Placental Transforming Growth Factor-beta Gene Transcription to Prevent Apoptosis and Allow Cell Cycle Progression of Human Mammary Carcinoma Cells
J. Biol. Chem., July 12, 2002; 277(29): 26662 - 26672.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. L. Brockman, M. D. Schroeder, and L. A. Schuler
PRL Activates the Cyclin D1 Promoter Via the Jak2/Stat Pathway
Mol. Endocrinol., April 1, 2002; 16(4): 774 - 784.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society